(Q35036732)

5 August 2017

1 reference

title

Gene therapy for the treatment of oral squamous cell carcinoma (English)

1 reference

oral squamous cell carcinoma

5 August 2017

0 references

1 reference

Xi S

1

1 reference

PubMed ID

12508038

5 August 2017

Grandis JR

series ordinal

2

1 reference

PubMed ID

12508038

5 August 2017

language of work or name

English

0 references

publication date

1 January 2003

1 reference

Journal of Dental Research

5 August 2017

1 reference

5 August 2017

82

1 reference

5 August 2017

11-16

1 reference

5 August 2017

1

1 reference

Electroporation therapy for head and neck cancer including carotid artery involvement

5 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F154405910308200104

Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154405910308200104

p21(WAF1/Cip1) retards the growth of human squamous cell carcinomas in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154405910308200104

TGF-alpha antisense gene therapy inhibits head and neck squamous cell carcinoma growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154405910308200104

Local inflammation and devascularization--in vivo mechanisms of the "bystander effect" in VPC-mediated HSV-Tk/GCV gene therapy for human malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154405910308200104

Suicide gene therapy for human oral squamous cell carcinoma cell lines with adeno-associated virus vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154405910308200104

Gene therapy for head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154405910308200104

A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad.HSV-tk and Ad.mIL-12 gene therapies in experimental prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154405910308200104

Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154405910308200104

Folate-targeted gene transfer in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154405910308200104

Light-induced adenovirus gene transfer, an efficient and specific gene delivery technology for cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154405910308200104

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154405910308200104

Preclinical study on gene therapy of cervical carcinoma using adeno-associated virus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154405910308200104

Combination nonviral interleukin 2 and interleukin 12 gene therapy for head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154405910308200104

Inhibition of human T-cell leukemia virus type 1 replication by antisense env oligodeoxynucleotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154405910308200104

Therapy of head and neck squamous cell carcinoma with an oncolytic adenovirus expressing HSV-tk

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154405910308200104

Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154405910308200104

Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. Head and Neck Interferon Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154405910308200104

Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154405910308200104

Gene gun-mediated oral mucosal transfer of interleukin 12 cDNA coupled with an irradiated melanoma vaccine in a hamster model: successful treatment of oral melanoma and distant skin lesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154405910308200104

Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154405910308200104

Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154405910308200104

Transferrin-liposome-mediated p53 sensitization of squamous cell carcinoma of the head and neck to radiation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154405910308200104

Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154405910308200104

10.1177/154405910308200104

21 January 2018

Identifiers

DOI

1 reference

5 August 2017

1 reference

PubMed ID

12508038